...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry
【24h】

Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry

机译:uPAR免疫组织化学评估下食道,胃食管连接和and门腺癌的预后

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase-type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high-grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR-immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR-positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR-score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR-scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)-stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR-positive macrophages. Scoring of uPAR-positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.
机译:下食道腺癌,胃食管交界处和card门腺癌是高浸润性肿瘤,预后较差。确定了66例患者中尿激酶型纤溶酶原激活剂受体(uPAR)的定位。腺癌60例,巴雷特食管6例。在几乎所有浸润性腺癌病例中,uPAR在浸润前沿和肿瘤核心处都由癌细胞,巨噬细胞和成肌纤维细胞群体表达。在高度不典型增生或肿瘤组织附近有Barrett上皮化生的区域,未发现uPAR免疫反应性。因此,uPAR的高局部表达似乎是该肿瘤中侵袭行为的特征性标志,表明uPAR在侵袭性生长过程中对基质降解的贡献是致癌作用的晚期事件。使用评分系统对免疫组织化学染色标本上的uPAR阳性值进行半定量评估,发现肿瘤核心处的癌细胞和肿瘤浸润区周围的巨噬细胞的总生存期较差,且uPAR得分较高。在多变量分析中,这两个uPAR评分被确认为高度重要的预后参数,与肿瘤,淋巴结转移(TNM)阶段和世界卫生组织(WHO)的分类无关。因此,这些恶性和非恶性辅助细胞的蛋白水解作用似乎遵循两种主要模式:一种由uPAR阳性癌细胞控制,另一种由uPAR阳性巨噬细胞控制。 uPAR阳性评分可能是这些腺癌开始侵袭和预后的有用参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号